Patents Assigned to Jagotec AG
-
Patent number: 8697755Abstract: The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.Type: GrantFiled: July 16, 2010Date of Patent: April 15, 2014Assignee: Jagotec AGInventor: Guy Vergnault
-
Patent number: 8663693Abstract: Nanoparticles and nanoparticle formulations or suspensions are provided which comprise a fibrate and vitamin E TPGS. The nanoparticles may have a mean diameter, measured by photon correlation spectroscopy, in the range of from about 100 nm to about 900 nm. Pharmaceutical formulations and uses of such compositions are also provided.Type: GrantFiled: August 9, 2002Date of Patent: March 4, 2014Assignee: Jagotec AGInventors: Pascal Grenier, Guy Vergnault, Alain Nhamias
-
Patent number: 8586094Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: May 2, 2003Date of Patent: November 19, 2013Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadesh, Robert A. Snow, Pol-Henri Guivarc'H
-
Patent number: 8568748Abstract: The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.Type: GrantFiled: December 14, 2001Date of Patent: October 29, 2013Assignee: JAGOTEC AGInventors: Johannes Wohlrab, Reinhard Neubert, Konstanze Jahn
-
Patent number: 8460706Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.Type: GrantFiled: February 7, 2011Date of Patent: June 11, 2013Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
-
Publication number: 20130122061Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: ApplicationFiled: December 13, 2012Publication date: May 16, 2013Applicant: JAGOTEC AGInventor: Jagotec AG
-
Publication number: 20130108695Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the: fluid with its heavier end pointing: generally; downwards and into the fluid.Type: ApplicationFiled: July 4, 2011Publication date: May 2, 2013Applicant: JAGOTEC AGInventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Patent number: 8415329Abstract: Compositions of submicron- to micron-sized particles of water-insoluble biologically active substances that are stabilized by thermoprotecting agents, can be terminally steam sterilized without any significant increase of mean particle size. These compositions display markedly reduced heat-induced coagulation, flocculation, or particle size growth during the terminal steam sterilization process.Type: GrantFiled: May 28, 1999Date of Patent: April 9, 2013Assignee: Jagotec AGInventor: Awadhesh K. Mishra
-
Patent number: 8414867Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.Type: GrantFiled: August 17, 2012Date of Patent: April 9, 2013Assignee: Jagotec AGInventors: Rudi Mueller-Walz, Roland Steiner
-
Publication number: 20130079415Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.Type: ApplicationFiled: February 16, 2011Publication date: March 28, 2013Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier
-
Patent number: 8394407Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: March 23, 2012Date of Patent: March 12, 2013Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Publication number: 20130014758Abstract: A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.Type: ApplicationFiled: August 17, 2012Publication date: January 17, 2013Applicant: Jagotec AGInventors: Rudi Mueller-Walz, Roland Steiner
-
Publication number: 20120328704Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Applicant: Jagotec AGInventor: Rudi Mueller-Walz
-
Patent number: 8309124Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: March 19, 2012Date of Patent: November 13, 2012Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Publication number: 20120282189Abstract: The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronised pa-agonist; b) micronised corticosteroid; c) a siib-therapexrtic quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.Type: ApplicationFiled: October 15, 2010Publication date: November 8, 2012Applicant: Jagotec AGInventors: Rudi Mueller-Walz, Lise-Marie Fueg
-
Patent number: 8303986Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.Type: GrantFiled: June 5, 2009Date of Patent: November 6, 2012Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
-
Publication number: 20120213910Abstract: The present invention describes a pharmaceutical dosage form with site- and time-controlled gastrointestinal release of active ingredient.Type: ApplicationFiled: March 15, 2012Publication date: August 23, 2012Applicant: Jagotec AGInventors: Achim Schaeffler, Pascal Grenier, Guy Vergnault
-
Patent number: 8246935Abstract: A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.Type: GrantFiled: October 27, 2011Date of Patent: August 21, 2012Assignee: Jagotec AGInventors: Rudi Mueller-Walz, Roland Steiner
-
Publication number: 20120196938Abstract: The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.Type: ApplicationFiled: July 16, 2010Publication date: August 2, 2012Applicant: Jagotec AGInventor: Guy Vergnault
-
Publication number: 20120177739Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan